Anti‐inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitorCHF6001 on virus‐inducible cytokines
Open Access
- 15 January 2016
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 4 (1) , e00202
Abstract
Respiratory virus infections precipitate asthma and chronic obstructive pulmonary disease (COPD) exacerbations, with most exacerbations due to rhinovirus infection. Both asthma andCOPDexacerbations are not well controlled by steroid therapies, and there is a much research interest in finding improved therapies or combinations of therapies for controlling exacerbations.CHF6001 is a new, inhaled highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor. Using in vitro human bronchial epithelial cells (BEAS‐2B), we investigated the potential anti‐inflammatory effects ofCHF6001 on rhinovirus (RV1B)‐induced cytokines. CytokinemRNAwas measured by real‐timePCR, while protein release was measured byELISA.CHF6001 was used in a 7‐point dose–response curve (1000–0.001 nmol/L) as a 1.5‐h pretreatment prior to infection in comparison with roflumilast. Both roflumilast andCHF6001 reducedRV1B‐inducedIL‐8,IL‐29,IP‐10, and RANTES mRNA and protein in a concentration‐dependent manner. Generally,CHF6001 was 13‐ to 16‐fold more potent (subnanomolarEC50values) than roflumilast at reducingIL‐8,IL‐29,IP‐10, andRANTES mRNAand protein release, but had similar efficacies. In combination with the steroid fluticasone propionate (1 nmol/L),CHF6001 had additive effects, significantly reducingRV‐induced cytokines when compared with steroid orCHF6001 alone. Combined low‐dose steroid and low‐doseCHF6001 had a similar efficacy as high‐dose steroid orCHF6001 alone, indicating the combination had steroid andPDE4 inhibitor sparing effects. Overall results indicate thatPDE4 inhibitors have anti‐inflammatory activity against virus‐induced inflammatory mediators and thatCHF6001 is more potent than roflumilast.Keywords
Funding Information
- Chiesi Farmaceutici
This publication has 63 references indexed in Scilit:
- Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory DiseasesJournal of Medicinal Chemistry, 2014
- Defining critical roles for NF‐κB p65 and type I interferon in innate immunity to rhinovirusEMBO Molecular Medicine, 2012
- Roflumilast inhibits the release of chemokines and TNF‐α from human lung macrophages stimulated with lipopolysaccharideBritish Journal of Pharmacology, 2011
- Association between human rhinovirus C and severity of acute asthma in childrenEuropean Respiratory Journal, 2010
- A Major Functional Role for Phosphodiesterase 4D5 in Human Airway Smooth Muscle CellsAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- The effect of oxidative stress on macrophages and lung epithelial cells: The role of phosphodiesterases 1 and 4Toxicology Letters, 2007
- Budesonide/Formoterol Maintenance Plus Reliever TherapyChest, 2006
- A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitroJournal of Allergy and Clinical Immunology, 2006
- Comparison of roflumilast, an oral anti‐inflammatory, with beclomethasone dipropionate in the treatment of persistent asthmaAllergy, 2005
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003